Related Experiment Video
Updated: May 10, 2025
04:23
The Creation of a Rat Model for Osteosarcopenia via Ovariectomy
Published on: February 21, 2025
176
Impact of GLP- 1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia
Zoe Memel1, Stephanie L Gold2, Michelle Pearlman3
1Department of Gastroenterology, University of California San Francisco, San Francisco, California, USA.
Current Nutrition Reports
|April 27, 2025
Summary
Glucagon-like peptide-1 receptor agonists (GLP-1 RA) can cause significant muscle loss. High-protein diets and resistance training may help mitigate this risk in vulnerable patients.
Area of Science:
- Endocrinology
- Geriatrics
- Metabolic Diseases
Background:
- Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are increasingly prescribed for chronic diseases.
- GLP-1 RA contribute to substantial weight loss, but can also lead to significant lean body mass reduction.
Purpose of the Study:
- To review factors contributing to accelerated muscle loss in patients using GLP-1 RA.
- To describe interventions for reducing sarcopenia and frailty risk in these populations.
Main Methods:
- Literature review of studies on GLP-1 RA and body composition.
- Analysis of risk factors for sarcopenia in specific patient groups.
- Identification of potential nutritional and exercise interventions.
Main Results:
- GLP-1 RA can cause 15-40% of weight loss to be lean body mass.
- Populations at risk include older adults and those with chronic kidney, liver, or inflammatory bowel diseases.
- High protein intake and resistance training show promise in preventing muscle loss.
Conclusions:
- GLP-1 RA necessitate targeted interventions to prevent accelerated sarcopenia.
- Individualized nutrition and exercise plans focusing on protein and resistance training are crucial.
- Further research is needed on GLP-1 RA's impact on sarcopenia in high-risk groups.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133
01:23Dipeptidyl Peptidase 4 Inhibitors
117
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
117
01:06Oral Hypoglycemic Agents: Glinides
109
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
109
01:15Hypoglycemia and Glucagon
134
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
134
01:16Insulin: Dosing Regimen and Adverse Effects
121
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
121